CIITA Human siRNA Oligo Duplex (Locus ID 4261)

CAT#: SR302895

CIITA (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each


USD 518.00

In Stock*

Size
    • 1 kit

Product Images

Frequently bought together (3)
siTran 2.0 siRNA transfection reagent (0.5ml)
    • 500 ul

USD 271.00


Trilencer-27 Fluorescent-labeled transfection control siRNA duplex - 1 nmol
    • 1 nmol

USD 142.00


CIITA mouse monoclonal antibody,clone OTI7B12
    • 100 ul

USD 447.00

Other products for "CIITA"

Specifications

Product Data
Purity HPLC purified
Quality Control Tested by ESI-MS
Sequences Available with shipment
Components CIITA (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 4261)
Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol
Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml
Stability One year from date of shipment when stored at -20°C.
Number of Transfections Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
Note Single siRNA duplex (10nmol) can be ordered.
Reference Data
RefSeq NM_000246, NM_001286402, NM_001286403, NR_104444
UniProt ID P33076
Synonyms C2TA; CIITAIV; MHC2TA; NLRA
Summary This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the "master control factor" for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]
Performance Guaranteed OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).

{0} Product Review(s)

0 Product Review(s) Submit review

Be the first one to submit a review

Product Citations

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.